Administrative Core
Administrative Core
批准号:
10513914
负责人:
David S Perlin
金额:
$755.88万
依托单位国家:
美国
项目类别:
财政年份:
2022
资助国家:
美国
项目状态:
未结题
起止时间:
2022-05-16 至 2025-04-30
关键词:
2019-nCoVAcademiaAddressAgreementAntiviral AgentsBiotechnologyBusinessesDecision MakingDevelopmentEnsureFosteringGoalsHealthHealthcare SystemsIndividualIndustryInstitutionIntellectual PropertyInvestigational DrugsLeadLeadershipLicensingLogisticsMediationMedicineMentorsMeridiansNational Institute of Allergy and Infectious DiseaseNew JerseyOnline SystemsOutcomeOutputPerformancePharmaceutical ChemistryPharmacologyPress ReleasesProcessProgress ReportsPublicationsReportingResearchResearch Project GrantsResource AllocationResourcesRiceRightsRiskScheduleSecureSite VisitStructureTimeTravelUnited States National Institutes of HealthVirusantiviral drug developmentbaseconflict resolutiondata sharingdesigndrug developmentdrug discoveryexperienceindustry partnerinnovationmaterial transfer agreementmeetingsmembermetropolitanorganizational structurepandemic diseasepre-clinicalpreclinical developmentprogramssuccessvirology
中文摘要
点击翻译按钮获取中文摘要
英文摘要
The MAVDA Administrative Core (MAC) will be established as an integrated, priority-setting consortium
involving the Program Directors (PDs), a Business Director (BD), an internal MAVDA Leadership Team (MLT),
and a Scientific Advisory Board (SAB) with programmatic involvement from NIAID to enhance potential product
outcome in the form of antivirals against SAR-CoV-2 and other viruses with pandemic potential. The
management function is designed to provide administrative support that facilitates the success of individual
projects, promotes effective integration and allocation of support functions and resources, and stimulates
scientific exchange between MAVDA members, thus ensuring that the overall program achieves its objectives.
The MAC will be overseen by co-PDs, Dr. David S. Perlin and Dr. Charles M. Rice, who will be supported by an
experienced BD and appropriate support staff to coordinate and manage all administrative functions. To best
advance MAVDA's objectives, the MAC will coordinate regular meetings of Project Leaders, Pharma/Biotech
Partners, Core Directors, and SAB members. The meetings are designed to advance compounds through the
discovery matrix enabling timely and objective ‘Go/No Go’ decision making. A secure web-based platform will
be used to foster interactions between Projects and Cores. The MAC will facilitate an annual review meeting with
the SAB, and a reverse site visit at NIAID. It will produce and submit the annual progress report to the NIH, and
it will coordinate research publications, meeting presentations, reports and press releases. MAVDA is designed
to encourage partnering among academia and industry, specifically Pharma and Biotech companies, and has
protections in place to protect the intellectual property of participating organizations. There is universal
confidentiality between projects and cores, with data shared as required to advance compounds and at no risk
to the project team. As MAVDA retains no IP rights, all IP rights reside in the host institutions or per agreements
with industry partners. The MAC will execute the following Specific Aims: 1) establish a highly efficient
management structure that supplies essential oversight and guidance for Project Leaders and Core Directors,
effectively integrates the Scientific Advisory Board as strategic advisors in the discovery process, and promotes
scientific exchange; 2) maximize allocation of resources and prioritize compound development by establishing
critical metrics for ‘Go/No Go’ decision making and resource allocations by supporting close interactions of
Project Leaders and Core Directors and scheduling regular reviews; 3) annually assess project performance and
prepare interim and year-end reports; 4) solicit and manage Developmental and Mentored Research Projects;
5) coordinate publications, presentations of results, and press releases from these studies and develop a
managerial plan for conflict resolution and other operational issues; and 6) establish an internal organizational
structure that addresses logistics for material transfer agreements, intellectual property filings, licensing
opportunities, and negotiations.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Accelerated development of advanced leads against SARS-CoV-2 and other pandemic viruses
-
批准号:10513922
-
项目类别:
-
资助金额:$388.58万
-
财政年份:2022
-
负责人:David S Perlin
-
依托单位:
Metropolitan AntiViral Drug Accelerator
-
批准号:10513913
-
项目类别:
-
资助金额:$6514.17万
-
财政年份:2022
-
负责人:David S Perlin
-
依托单位:
Animal Model Core
-
批准号:10513920
-
项目类别:
-
资助金额:$558.04万
-
财政年份:2022
-
负责人:David S Perlin
-
依托单位:
A CETR-based partnership accelerator for rapid drug development targeting SARS-CoV-2 and pan-CoVs
-
批准号:10187269
-
项目类别:
-
资助金额:$61.99万
-
财政年份:2020
-
负责人:David S Perlin
-
依托单位:
Critical Factors Influencing Echinocandin Resistance in Candidaglabrata
-
批准号:10451830
-
项目类别:
-
资助金额:$71.06万
-
财政年份:2019
-
负责人:David S Perlin
-
依托单位:
Center to develop innovative therapeutics to multidrug resistant high-threat bacterial agents
-
批准号:10394984
-
项目类别:
-
资助金额:$663.83万
-
财政年份:2019
-
负责人:David S Perlin
-
依托单位:
Novel bi-specific immunoprophylactics against multi-drug resistant Gram-negativebacterial infections
-
批准号:10380759
-
项目类别:
-
资助金额:$107.68万
-
财政年份:2019
-
负责人:David S Perlin
-
依托单位:
Novel bi-specific immunoprophylactics against multi-drug resistant Gram-negative bacterial infections
-
批准号:9898899
-
项目类别:
-
资助金额:$107.06万
-
财政年份:2019
-
负责人:David S Perlin
-
依托单位:
Critical Factors Influencing Echinocandin Resistance in Candidaglabrata
-
批准号:10215271
-
项目类别:
-
资助金额:$71.06万
-
财政年份:2019
-
负责人:David S Perlin
-
依托单位:
Novel bi-specific immunotherapeutic against high-threat Gram-negative pathogens
-
批准号:10337197
-
项目类别:
-
资助金额:$114.2万
-
财政年份:2019
-
负责人:David S Perlin
-
依托单位:
Core E Animal Infection Models
-
批准号:10394989
-
项目类别:
-
资助金额:$118.1万
-
财政年份:2019
-
负责人:David S Perlin
-
依托单位:
Center to develop innovative therapeutics to multidrug resistant high-threat bacterial agents
-
批准号:9923564
-
项目类别:
-
资助金额:$663.81万
-
财政年份:2019
-
负责人:David S Perlin
-
依托单位:
Core E Animal Infection Models
-
批准号:10613892
-
项目类别:
-
资助金额:$144.96万
-
财政年份:2019
-
负责人:David S Perlin
-
依托单位:
Administrative Core
-
批准号:10613884
-
项目类别:
-
资助金额:$73.49万
-
财政年份:2019
-
负责人:David S Perlin
-
依托单位:
Administrative Core
-
批准号:10394985
-
项目类别:
-
资助金额:$54.33万
-
财政年份:2019
-
负责人:David S Perlin
-
依托单位:
Novel bi-specific immunotherapeutic against high-threat Gram-negative pathogens
-
批准号:10551227
-
项目类别:
-
资助金额:$114.2万
-
财政年份:2019
-
负责人:David S Perlin
-
依托单位:
Center to develop innovative therapeutics to multidrug resistant high-threat bacterial agents
-
批准号:10613883
-
项目类别:
-
资助金额:$652.13万
-
财政年份:2019
-
负责人:David S Perlin
-
依托单位:
Novel bi-specific immunoprophylactics against multi-drug resistant Gram-negative bacterial infections
-
批准号:9926819
-
项目类别:
-
资助金额:$105.13万
-
财政年份:2019
-
负责人:David S Perlin
-
依托单位:
Critical Factors Influencing Echinocandin Resistance in Candida glabrata
-
批准号:8614663
-
项目类别:
-
资助金额:$48.77万
-
财政年份:2014
-
负责人:David S Perlin
-
依托单位:
Center to develop therapeutic countermeasures to high-threat bacterial agents
-
批准号:8642305
-
项目类别:
-
资助金额:$539.91万
-
财政年份:2014
-
负责人:David S Perlin
-
依托单位:
海外基金